Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1991; 66(01): 001-005DOI: 10.1055/s-0038-1646366 Review Article Schattauer GmbH Stuttgart Role of Thrombin in Arterial Thrombosis: Implications for Therapy James H Chesebro , Pierre Zoldhelyi , Lina Badimon , Valentin Fuster Recommend Article Abstract PDF Download Buy Article PDF (1268 kb) References References 1 Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro JH. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988; 77: 1213-1220 2 Steele PM, Chesebro JH, Stanson AW, Holmes DR, Dewanjee M, Badimon L, Fuster V. Balloon angioplasty: A natural history of the pathophysiologic response to injury in a pig model. Circ Res 1985; 57: 105-112 3 Heras M, Chesebro JH, Penny WJ. et al Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation 1988; 78: 654-660 4 Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657-665 5 Heras M, Chesebro JH, Webster MWI. et al. Hirudin, heparin, and placebo during deep arterial injury in the pig: The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990; 82: 1476-1484 6 Lam JYT, Chesebro JH, Steele PM, Fuster V. Is vasospasm related to platelet deposition? in vivo relationship in a pig model of arterial injury. Circulation 1987; 75: 243-248 7 Fuster V, Stein B, Badimon L, Chesebro JH. Antithrombotic therapy after myocardial reperfusion in acute myocardiol infarction. J Am Coll Cardiol 1988; 12 (6) 78A-84A 8 Lam JYT, Chesebro JH, Fuster V. Platelets, vasoconstriction, and nitroglycerin during arterial wall injury: a new antithrombotic role for an old drug. Circulation 1988; 78: 712-716 9 Fischell TA, Derby G, Tse TM, Stadius ML. Coronary artery vasoconstriction routinely occurs after percutaneous transluminal coronary angioplasty: A quantitative arteriographic analysis. Circulation 1988; 78: 1323-1334 10 Heras M, Chesebro JH, Thompson PL, Fuster V. Prevention of early and late rethrombosis and further strategies after coronary reperfusion. In: Thrombolysis in Cardiovascualar Diseases. (Eds: Julian D, Kubler W, Norris Rm, Swan HJC, Collen D, Verstraete M. ) Marcel Dekker Inc, New York: 1989: 203-229 11 Califf RM, Topol EJ, George BS. Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: Results of the Thrombolysis and Angioplasty in Myocardial Infaction (TAMI) I trial. Circulation 1988; 77: 1090-1099 12 Baim DS, Diver DJ, Knatterud GL. PTCA "salvage" for thrombolytic failures-implications from TIMI II-A. Circulation 1988; 78 (suppl II) II-112 13 Mabin TA, Holmes DR, Smith HC. et al. Intracoronary thrombus: role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985; 5 (2) 198-202 14 Theroux P, Ouimet H, McCans J. et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-1111 15 Badimon L, Lassila R, Badimon J, Vallabhajosula S, Chesebro JH, Fuster V. Residual thrombus is more thrombogenic than severely damaged vessel wall. Circulation 1988; 78 (Suppl II) II-119 16 Seegers WH, Nieft M, Loomis EC. Note of the absorption of thrombin on fibrin. Science 1945; 101: 520-521 17 Liu CY, Nossel HL, Kaplan KL. The binding of thrombin by fibrin. J Biol Chem 1979; 254: 10421-10425 18 Francis CW, Markham RE Jr., Barlow GH. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220-230 19 Kaminski M, McDonagh J. Studies on the mechanism of thrombin: Interaction with fibrin. J Biol Chem 1983; 258: 10530-10535 20 Berliner LJ, Sugawara Y. Human -thrombin binding to nonpolymerized fibrin-sepharose: Evidence for an anionic binding region. Biochem 1985; 24: 7005-7009 21 Kaminski MMcDonagh. Inhibited thrombins: Interactions with fibrinogen and fibrin. Biochem J 1987; 242: 881-887 22 Vali Z, Scheraga HA. Localization of the binding site on fibrin for the secondary binding site of thrombin. Biochem 1988; 27: 1956-1963 23 Shuman MA. Thrombin-cellular interactions. Ann NY Acad Sci 1986; 485: 228-239 24 Mruk JS, Chesebro JH, Webster MWI. Platelet aggregation and interaction with the coagulation system: Implications for antithrombotic therapy in arterial thrombosis. J Corn Art Dis 1990; 1: 149-158 25 Fitzgerald DJ, Catella F, Roy L, Fitzgerald GA. Marked platelet activation in vivo after intravenous streptonkinase in patients with acute myocardial infarction. Circulation 1988; 7 7(1) 142-150 26 Eisenberg PR, Sherman L, Rich M. et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986; 75: 1255-1262 27 Owen J, Friedman KD. Grossman: Thrombolytic therapy with tissue plasminogen activity. Blood 1988; 7 2(2) 616-620 28 Fitzgerald DJ, Wright F, Fitzgerald GA. Thrombin-mediated platelet activation during coronary thrombolysis. Circulation 1988; 78 (suppl II) II-120 29 Cercek B, Lew AS, Hod H. et al. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 1986; 7 4(3) 583-587 30 Cercek B, Lew AS, Sato Y. et al. Haparin enhances experimental thrombolysis by preventing new fibrin deposition. Circulation 1985; 72 (Suppl III) III-194 31 Tomaru T, Uchida Y, Nakamura F. et al. Enhancement of arterial thrombolysis with native tissue type plasminogen activator by pretreatment with heparin or batroxobin: An angioscopic study. Am Heart J 1989; 117: 275-281 32 Golino P, Ashton JH, McNatt J. et al. Simultaneous administration of thromboxane A2-and serotonin S2-receptor antagonists remarkedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis. Circulation 1989; 79: 911-919 33 Jang IK, Gold H, Ziskind AA. et al. Differential sensitivity of erythrocyterich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79: 920-928 34 Fay WP, Owen WG. Platelet plasminogen activator inhibitor: purification and characterization of interaction with plasminogen activators and activated protein C inhibitor. Biochem 1989; 28: 5773-5778 35 Lam JYT, Chesebro JH, Badimon L, Fuster V. Serotonin and thromboxane A2 receptor blockade decrease vasoconstriction but not platelet deposition after deep arterial injury. Circulation 1986; 74 (Suppl II) II-97 36 Markwardt F, Kaiser B, Novak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res 1989; 54: 377-388 37 Ambler J, Butler KD, Kerry R. et al. Comparative effects of selective thrombin inhibition by hirudin on coagulation and thrombosis. Circulation 1989; 80 (Suppl II) II-316 (Also personal communication with R.B. Wallis.) 38 Badimon L, Badimon JJ, Cohen M, Chesebro JH, Fuster V. Thrombosis formation in stenotic and laminar flow conditions: Effect on an antiplatelet GPIIb/IIIa monclonal antibody fragment [7E3F(ab'2]. Circulation 1989; 80 (Suppl II) II-422 39 Gold HK, Boston MA. personal communication 40 Badimon L, Badimon J, Lassila R, Heras M, Chesebro JH, Fuster V. Thrombin inhibition by hirudin decreases platelet thrombus growth on areas of severe wall injury. J Am Coll Cardiol 1989; 13: 145A 41 Mao SJ T, Yates MT, Owen TJ. et al. Interaction of hirudin with thrombin: Identification of a minimal binding domain of hirudin that inhibits clotting activity. Biochem 1988; 27: 8170-8173 42 Tam WS, Fenton JW, Detwiler TC. Dissociation of thrombin from platelets by hirudin. J Biol Chem 1979; 254: 8723-8725 43 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin anti-thrombin III: Implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-3623 44 Weitz JI, Hudoba M, Massel D, Maranganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptable to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391 45 Massel DR, Hudoba M, Weitz JI. Clot-bound thrombin is protected from heparin inhibition-a potential mechanisms for rethrombosis after lytic therapy. Circulation 1989; 80 (Suppl II) II-420 46 Rentrop KP, Feit F, Blanke H. et al. Effects of intracoronary streptokinase and intracoronary nitroglycerin infusion on coronary angiographic patterns and mortality in patients with acute myocardial infarction. N Engl J Med 1984; 311: 1457-1463 47 Douglas Jr JS, Lutz JF, Clements SD. et al. Therapy of large intracoronary thrombi in candidates for percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1988; 11: 238A 48 Nakagawa S, Hanada Y, Koiwaya Y. et al. Angiographic features in the infarct-related artery after intracoronary urokinase follwed by prolonged anticoagulation. Role of ruptured atheromatous plaque and adherent thrombus in acute myocardial infarction in vivo. . Circulation 1988; 78: 1335-1344 49 Bar-Shavit R, Eldora A, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix: Protection and expression of functional properties. J Clin Invest 1989; 84: 1096-1104 50 Jaffe EA, Hoyer LW, Nachman RL. Synthesis of vonWillebrand Factor by cultured human endothelial cells. Proc Natl Acad Sci USA 1974; 71: 1906-1909 51 Knudson BS, Silverstein RL, Leung LLK, Harpel PC, Nachman RL. Binding of plasminogen to extracellular matrix. J Biol Chem 1986; 261: 10765-10771 52 Smith JC, Singh JP, Lillquist JS, Goon DS, Stiles CD. Growth factors adherent to cell substrate are mitogenically active in situ. Nature (Lond) 1982; 296: 154-156 53 Hatton MWC, Moar SL. A role for pericellular proteoclycan in the binding of thrombin or antithrombin III by the blood vessel endothelium. The effects of proteoglycan-degrading enzymes and glycosaminoglycan-binding proteins on 125I-thrombin binding by rabbit thoracic aorta in vitro. . Thromb Haemostasis 1985; 53: 228-234 54 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyly-arginyl chlormethyl ketone. Proc Natl Acad Sci USA 1988; 85: 3184-3188 55 Harker LA, Atlanta GA. personal communication 56 Williams EB, Krishnaswamy S, Mann KG. Zymogen/enzyme discrimination using peptide chlormethyl ketones. J Biol Chem 1989; 264: 7536-7545 57 Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochem 1986; 25: 4622 58 Webster MWI, Chesebro JH, Heras M, Mruk JS, Grill DE, Fuster V. Short-term intravenous hirudin during balloon dilatation does not prevent platelet-thrombosis 48 hours after deep arterial injury. J Am Coll Cardiol 1991 (in press) 59 Jang I-K, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich thrombosis by selective thrombin inhibition. Circulation 1990; 81: 219-225 60 Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang I-K, Hold R, Fallon JT, Collen D. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990; 16: 714-722 61 Fitzgerald DJ, FitzGerald GA. Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci 1989; 86: 7885-9 62 Jang I-K, Gold HK, Leinbach RC, Fallon JT, Collen D. in vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res 1990; 67: 1552-1561 63 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues: Implications for disorders of hemostasis and thrombosis. Am J Patjol 1989; 134: 1087-1097 64 Drake TA, Morrissey JH, Edgington TS. Immunohistochemical detection of tissue factor in human atherosclerotic plaques. Circulation 1989; 80 (Suppl II) II-182 65 Jang I-K, Gold HK, Leinbach RG, Fallon JT, Bunting S, Collen D, Wilcox JN. A monoclonal antibody against tissue factor prevents platelet-rich arterial thrombosis in the rabbit. J Am Coll Cardiol 1990; 15: 188A 66 Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Badimon L, Fuster V. Antithrombotic efficacy of low molecular weight heparin after arterial injury in the pig. J Am Coll Cardiol 1990; 15: 188A 67 Meletich JP, Jackson CM, Majerus PW. Properties of the factor Xa binding site on human platelets. J Biol Chem 1978; 6908-6916 68 Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by the heparin-antithrombin complex. J Clin Invest 1983; 71: 1383-1391 69 Sturzebecher J, Sturzebecher U, Viewieg H, Wagner G, Hauptmann J, Markwardt F. Synthetic inhibitors of bovine factor Xa and thrombin: Comparison of their anticoagulant efficiency. Thromb Res 1989; 54: 245-252 70 Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990; 248: 593-596 71 Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990; 15: 1667-1687
